Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

20.16
-0.5400-2.61%
Post-market: 20.160.00000.00%19:08 EST
Volume:1.41M
Turnover:28.51M
Market Cap:2.58B
PE:116.93
High:20.62
Open:20.49
Low:20.02
Close:20.70
52wk High:30.48
52wk Low:16.10
Shares:127.83M
Float Shares:78.12M
Volume Ratio:0.59
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1724
EPS(LYR):0.1724
ROE:7.48%
ROA:3.53%
PB:6.96
PE(LYR):116.93

Loading ...

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Reuters
·
Nov 25, 2025

Apellis Pharmaceuticals General Counsel David Watson Reports Sale of Common Shares

Reuters
·
Nov 18, 2025

H.C. Wainwright Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Nov 15, 2025

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

Benzinga_recent_news
·
Nov 13, 2025

Apellis Pharmaceuticals: Safety Profile of Syfovre Through Five Years Remained Consistent With Previously Reported Data

THOMSON REUTERS
·
Nov 12, 2025

Apellis Announces 5-Year Gale Data Showing Syfovre® (Pegcetacoplan Injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

THOMSON REUTERS
·
Nov 12, 2025

Apellis Reports SYFOVRE Delays Geographic Atrophy Progression by 1.5 Years in Five-Year Study

Reuters
·
Nov 12, 2025

Apellis Pharmaceuticals Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Nov 06, 2025

Wolfe Research Initiates Coverage on Apellis Pharmaceuticals With Peer Perform Rating

MT Newswires Live
·
Nov 06, 2025

J.P. Morgan Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Nov 05, 2025

Stock Track | Apellis Pharmaceuticals Plummets 5.05% as Mizuho Slashes Price Target

Stock Track
·
Nov 04, 2025

Stock Track | Apellis Pharmaceuticals Plunges 5% as Mizuho Slashes Price Target

Stock Track
·
Nov 04, 2025

Stock Track | Apellis Pharmaceuticals Plunges 5% Pre-Market as Multiple Analysts Cut Price Targets

Stock Track
·
Oct 31, 2025

Wedbush Lowers Price Target on Apellis Pharmaceuticals to $22 From $23, Keeps Neutral Rating

MT Newswires Live
·
Oct 31, 2025

Apellis Pharmaceuticals (APLS) Receives a Hold from RBC Capital

TIPRANKS
·
Oct 31, 2025

Apellis Pharmaceuticals (APLS) Receives a Hold from Morgan Stanley

TIPRANKS
·
Oct 31, 2025

Apellis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 31, 2025

Apellis price target lowered to $45 from $57 at H.C. Wainwright

TIPRANKS
·
Oct 31, 2025

U.S. RESEARCH ROUNDUP-Amazon, Apple, Cigna

Reuters
·
Oct 31, 2025

Apellis price target lowered to $27 from $29 at BofA

TIPRANKS
·
Oct 31, 2025